Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
Government Shutdown Stymies U.S. Research Efforts
New Rochelle, NY, October 16, 2013—Over 73% of U.S. scientists responding to a Genetic Engineering & Biotechnology News (GEN) poll say that the current government shutdown is impacting their ability to carry out their research projects.
According to the GEN survey question, “Has the government shutdown affected your research projects?,” 39.7% replied significantly; 21.8% said moderately; 12% responded slightly; and 26.5% were not affected at all.
The results of the GEN survey echo the thoughts of officials at the American Society for Cell Biology, the Ludwig Institute for Cancer Research, and the University of California, San Diego. Their consensus was that American political shortsightedness has huge ramifications for the life science community right now and will continue to do so for the future. (You can read the story here.)
“Not only do these kinds of government actions hurt U.S. competitiveness on the global biotechnology stage but, more importantly, it hinders scientists’ abilities to come up with life-saving drugs and effective therapies for a host of serious diseases,” says John Sterling, editor in chief of GEN.